Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 466.4%, EPS grew 34.7%, free cash flow grew 9.97% and total debt fell 62.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYMR
Kymera Therapeutics, Inc. (KYMR) EV/Sales
As of 16 October 2026, Kymera Therapeutics, Inc. (KYMR) trades at a EV/Sales of 91.4×. Over the past ten years it has ranged from 0.0× (September 2020) to 208× (June 2026); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 146× | 171.50% |
| FY2024 | 53.8× | 282.32% |
| FY2023 | 14.1× | (29.43%) |
| FY2022 | 19.9× | (44.26%) |
| FY2021 | 35.8× | 56.08% |
| FY2020 | 22.9× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 101× | (30.68%) |
| Mar 2026 | 145× | (0.60%) |
| Dec 2025 | 146× | 43.96% |
| Sep 2025 | 101× | 59.31% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| KRYS Krystal Biotech, Inc. compare | 19.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| KYMR Kymera Therapeutics, Inc. | 91.4× |
| CYTK Cytokinetics, Incorporated compare | 121× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)